Abstract: Objective To systematically evaluate the effectiveness of atorvastatin combined with trimetazidine and atorvastatin alone in the treatment of patients with chronic heart failure. Methods Domestic and oversea databases such as PubMed and China Biomedical Literature Database were used and trimetazidine, atorvastatin and heart failure were chose as the main keywords. According to the inclusion and exclusion criteria, relevant literature was included. The search limits were set from database establishment until October 2019. After the data was extracted, the R test meta analysis package was used to perform meta-analysis on the included test data. Results This meta-analysis finally included 13 studies with a total of 1 265 patients. The results showed that, compared with the control group, the group of atorvastatin combined with trimetazidine could improve clinical effectiveness RR 1.20, 95%CI (1.13, 1.28), P<0.001, increase left ventricular ejection fraction (LVEF)SMD = 1.67, 95%CI (1.23, 2.11), P<0.001, reduce left ventricular end-diastolic dimension (LVEFD)SMD = -1.13, 95%CI (-1.42, -0.83), P<0.001, reduce left ventricular end systolic diameter (LVESD)SMD =-1.80, 95%CI (-2.04, -1.55), P<0.001, increase 6 min movement distance SMD = 1.14, 95%CI (0.98, 1.30), P<0.001, and reduce the level of brain natriuretic peptide (BNP)SMD = -1.35, 95%CI (-1.71, -1.00), P<0.001. Conclusions Compared with atorvastatin alone, the combined use of atorvastatin and trimetazidine plus conventional therapy can improve the overall clinical effectiveness of heart failure patients and improve cardiac function indicators.